[{"id":"7ee22b9c-eea6-45ba-bdc2-0adfd9a6a3e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07174908","created_at":"2025-09-20T07:06:19.138Z","updated_at":"2025-09-20T07:06:19.138Z","phase":"Phase 3","brief_title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","source_id_and_acronym":"NCT07174908","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-09-16"},{"id":"82aa52d7-b360-425e-8654-41b803764529","acronym":"","url":"https://clinicaltrials.gov/study/NCT06166836","created_at":"2023-12-12T19:19:13.831Z","updated_at":"2024-07-02T16:35:22.973Z","phase":"Phase 1/2","brief_title":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","source_id_and_acronym":"NCT06166836","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-01-18"},{"id":"4c8ef224-f9fb-4c0f-9c53-755646bf66ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04109456","created_at":"2022-11-22T16:57:30.683Z","updated_at":"2024-07-02T16:35:24.033Z","phase":"Phase 1","brief_title":"IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma","source_id_and_acronym":"NCT04109456","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-01-10"},{"id":"dbd3c702-b77e-4718-868a-acd3b8d02b5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05379946","created_at":"2022-05-18T11:57:01.770Z","updated_at":"2024-07-02T16:35:32.883Z","phase":"Phase 1/2","brief_title":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","source_id_and_acronym":"NCT05379946","lead_sponsor":"InventisBio Co., Ltd","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-10-18"},{"id":"ad1495a4-53c4-4b07-a3b2-a31c7fdfec87","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014528","created_at":"2023-08-28T14:08:40.926Z","updated_at":"2024-07-02T16:35:38.861Z","phase":"Phase 2","brief_title":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","source_id_and_acronym":"NCT06014528","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 09/06/2022","start_date":" 09/06/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-28"}]